Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05122936
Other study ID # SHMHTCM
Secondary ID
Status Enrolling by invitation
Phase
First received
Last updated
Start date November 30, 2021
Est. completion date November 14, 2027

Study information

Verified date March 2024
Source Shanghai Municipal Hospital of Traditional Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Obesity becomes a worldwide chronic health problem, including China. Meta-analyses showed in recent years anti-obesity effects of Chinese herbal therapy (CHT) in overweight and obese patients. However, there are still few observational studies on its effect in patients undergoing CHT more than 6 months, or on its safety. This is a mono-centric, prospective study conducted at Shanghai Municipal Hospital of Traditional Chinese Medicine. Patients with body mass index ≥ 28 Kg/m2 and chartered by heat-dampness is consecutively recruited. All the patients will undergo an integrated SRXPY-based Obesity Wellness Intervention (lifestyle invention + XRXP granule). Patients will be instructed by Traditional Chinese Medicine(TCM) practitioner and nutritionist. They will be investigated every 3 months, until 2 years after enrollment. The study will test anti-obesity effect and safety of the integrated obesity wellness intervention, and test changes of appetite, health-related quality of life, bio markers as well.


Description:

Obesity is a worldwide problem to public health, with a prevalence rate of 12.4% according to recent studies. It is associated with a series of chronic non-communicable diseases, including type 2 diabetes, cardiovascular diseases, non-alcoholic fatty liver, polycystic ovary syndrome, cancer, and so on. Many publications reported Chinese herbal therapy as an effective anti- obesity management. However, there are still few observational studies on its effect in patients undergoing Chinese herbal therapy more than 6 months, or on its safety. This is a mono-centric, prospective study conducted at Shanghai Municipal Hospital of Traditional Chinese Medicine. Patients with body mass index ≥ 28 Kg/m2 will be consecutively recruited in out-patient clinic of the department of endocrinology or nutrition. Another important including criteria is that each subject is supposed to be chartered by heat-dampness pattern in TCM. Patients will undergo an integrated SRXPY-based obesity wellness intervention(SOWI). They will report weekly diet, daytime physical activities and sleeping time, by means of WeChat and Electrical bracelet. Meanwhile, TCM practitioner and nutritionist will be involved in helping them. The integrated obesity wellness intervention is based on lifestyle invention and XRXP granule. XRXP granule is composed of several herbs, such as Huang Qin (Baical Skullcap Root), Zi Cao (Root of Sinkiang Arnebia), Hu Zhang (Rhizoma Polygoni cuspidata), Cang Shu (Atractylodis Rhizoma), He Ye (Lotus Leaf), etc. Some components have been found, which can ameliorate serum concentrations of glucagon-like peptide-1 by stimulating gut taste receptors in db/db mice. Also, XRXP granule showed anti-obesity effects (reduction of body weight, body mass index and waist circumstance) in a 12-week pilot study on obese patients. In this observational study, patients will be investigated every 3 months, until 2 years after enrollment. We will not only test the effect and safety, but test changes of appetite, health- related quality of life, bio markers as well.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 500
Est. completion date November 14, 2027
Est. primary completion date November 14, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: ·age ranged from 16-70 years old body mas index over 28kg/m2 Exclusion Criteria: - secondary cause of obesity such as hypothalamic obesity, cushing syndrome, and hypophysis dysfunction, etc. - pregnancy or lactation - significant dysfunction of heart, liver, kidney and systemic organs (NYHA Class III or IV; alanine aminotransferase(ALT) and / or aspartate aminotransferase(AST) = 5 times the normal upper limit; glomerular filtration rate< 60(ml/min) or with malignant tumor - body weight fluctuated by more than 5 kg in the last 3 months with drug abuse or alcohol addiction - with serious mental and neurological disorders - blood pressure = 180/110 mmHg, or malignant hypertension - organic and systemic diseases intolerant of herb

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
XRXPY-based Obesity Wellness Intervention(SOWI)
It is an integrated obesity wellness intervention, composing of lifestyle invention and Chinese herbal therapy (XRXP granule, twice daily, oral administration). XRXPY is made in accordance with standard procedures. Participants will be instructed by TCM practitioner and educated by nutritionist. They will perform diet self-report by WeChat, recording daytime physical active steps and all-day sleeping time by electric bracelet. All the participants will be followed every 2-4 weeks by means of out-patient clinic, phone call or WeChat.

Locations

Country Name City State
China Shanghai Municipal Hospital of Traditional Chinese Medicine Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Feng Tao

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Percent Change in Body Weight Measuring body weight at the required time point 2021-2027
Primary Percentage of Participants who Achieve =5% Body Weight Reduction Measuring body weight at the required time point 2021-2027
Secondary Percentage of participants who achieve =10% body weight reduction Measuring body weight at the required time point 2021-2027
Secondary Percentage of participants who achieve =15% body weight reduction Measuring body weight at the required time point 2021-2027
Secondary Change in waist circumference Measuring waist circumference at the required time point 2021-2027
Secondary Change in glycosylated hemoglobin A-1c(Hba1c) Measuring Hba1c at the required time point 2021-2027
Secondary Change in fasting blood glucose Measuring fasting blood glucose at the required time point 2021-2027
Secondary Change in Three-Factor eating questionnaire(TFEQ-R21) Investigating TFEQ-R21 at the required time point 2021-2027
Secondary Change in food craving questionnaire-trait(FCQ-T) Investigating FCQ-T at the required time point 2021-2027
Secondary Change in Impact of weight quality of life-lite(IWQOL-Lite) Investigating IWQOL-Lite at the required time point,higher scores indicate better quality of life on the IWQOL-Lite(0-100). 2021-2027
Secondary Change in the medical outcomes study item short from health survey-short from(SF-36) Investigating SF-36 at the required time point,higher scores indicate better quality of life on the SF-36(0-100). 2021-2027
Secondary Change in cholecystokinin(CCK) Measuring CCK in serum at the required time point 2021-2027
Secondary Change in bile acid Measuring bile acid in serum and feces at the required time point 2021-2027
Secondary Change in peptide YY(PYY) Measuring PYY in serum at the required time point 2021-2027
Secondary Change in ghrelin(GHRL) Measuring GHRL in serum at the required time point 2021-2027
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2